On Modeling The Disruption To Respiratory Clinical Trials
Novadiscovery announces Nature Communications paper on modeling the disruption to respiratory clinical trials due to mitigation measures against COVID-19
Lyon, France – 13 April 2022
Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the publication of a novel model of respiratory tract infections (RTI) in Nature Communications to address the uncertainties resulting from non-pharmaceutical interventions (NPIs) against COVID-19 on clinical trials. The paper was published in collaboration with NOVA’s partner OM Pharma.